I don't have CR fears YET. We had $1M cash as at Sept 30. $500k was forecast for Dec quarter (leaving $500k for March quarter). We are expecting $720k R&D rebate this quarter which we can assume has hit our acct (leaving us with c. $1.2M in cash post Dec quarter). Ordinarily, discounting the Compass deal, this should take us till the June quarter but we all shouldn't hope for that because it would mean there were no significant progress made on the regulatory approval front.
If FDA and CE approvals are achieved, we may need more money for our next steps (commercialisation of MEBSleep and MEB-001 pre-sub meetings and trial with FDA).
I expect revenue from Compass should be have been realised before the end of March quarter which is when I expect we may be running low on cash. If revenue is realised, we may not need to raise cash.
Anyway, if a CR eventuates it will be well north of where we are now considering the news pipeline.
Disclaimer: Speculations only. DYOR
MEB Price at posting:
1.2¢ Sentiment: Buy Disclosure: Held
